stoxline Quote Chart Rank Option Currency Glossary
  
SAB Biotherapeutics, Inc. (SABS)
3.47  -0.04 (-1.14%)    07-27 15:17
Open: 3.53
High: 3.635
Volume: 506,999
  
Pre. Close: 3.51
Low: 3.44
Market Cap: 33(M)
Technical analysis
2026-07-27 2:49:25 PM
Short term     
Mid term     
Targets 6-month :  4.49 1-year :  4.78
Resists First :  3.84 Second :  4.09
Pivot price 3.65
Supports First :  3.44 Second :  2.86
MAs MA(5) :  3.55 MA(20) :  3.72
MA(100) :  3.76 MA(250) :  3.39
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  9.7 D(3) :  15.2
RSI RSI(14): 40
52-week High :  5.15 Low :  1.85
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SABS ] has closed above bottom band by 16.0%. Bollinger Bands are 15.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.62 - 3.64 3.64 - 3.66
Low: 3.42 - 3.45 3.45 - 3.46
Close: 3.48 - 3.51 3.51 - 3.54
Company Description

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Headline News

Mon, 27 Jul 2026
SAB Biotherapeutics Inc (SABS) Valuation: PE, PB & Fair Value Analysis - TradingKey

Mon, 27 Jul 2026
SABS Technical Analysis & ETF Price Forecast - Intellectia AI

Mon, 27 Jul 2026
SAB Biotherapeutics Inc (SABS) Balance Sheet - TradingKey

Wed, 15 Jul 2026
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment - Yahoo Finance

Tue, 30 Jun 2026
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) - Yahoo Finance

Fri, 26 Jun 2026
SABS Forecast — Price Target — Prediction for 2027 - TradingView

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 76 (M)
Shares Float 41 (M)
Held by Insiders 0.8 (%)
Held by Institutions 92.4 (%)
Shares Short 4,380 (K)
Shares Short P.Month 2,880 (K)
Stock Financials
EPS -0.58
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -25.4 %
Return on Equity (ttm) -0.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -0.52
Sales Per Share 0
EBITDA (p.s.) -0.73
Qtrly Earnings Growth 0 %
Operating Cash Flow -51 (M)
Levered Free Cash Flow -27 (M)
Stock Valuations
PE Ratio -5.98
PEG Ratio 0
Price to Book value 1.15
Price to Sales 0
Price to Cash Flow -5.17
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android